invIOs GmbH
PrivateLast Round
Series A
Oct 15, 2024
Total Funding Raised
$8.94M
Company Overview
invIOs GmbH is a biotechnology company that develops next-generation cancer immunotherapies using its proprietary EPiC cell therapy platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
invIOs GmbH Comparables
Compare invIOs GmbH with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| HotSpot Therapeutics | 68% | |
| Adaptimmune Therapeutics | 68% | |
| Nurix Therapeutics, Inc. | 68% | |
invIOs GmbH Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 15, 2024 |
invIOs GmbH Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ligand Pharmaceuticals | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 15, 2024
$9M round led by Ligand Pharmaceuticals
invIOs GmbH Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about invIOs GmbH's valuation, stock price, and market status.